CJC-1295 W/DAC Spray

CJC-1295 W/DAC 5mg spray is a research-grade synthetic peptide solution developed for laboratory investigations involving growth hormone regulation, pituitary receptor kinetics, and non-invasive delivery methods. Chemically classified as a tetrasubstituted GHRH(1-29) analog conjugated to a maleimidopropionic acid linker (Drug Affinity Complex), its sequence is derived from the functional amino-terminal domain of native growth hormone-releasing hormone. To enhance biological stability, it incorporates four specific amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27, in addition to the C-terminal Lys(MPA) spacer. This design creates a molecular structure that is functionally distinct from native GHRH(1-29) (Sermorelin) and CJC-1295 No DAC variants.

From a molecular research perspective, CJC-1295 with DAC Spray provides a valuable model for investigating the dynamics of continuous, non-pulsatile endocrine receptor activation. Pituitary somatotrophs release growth hormone in specific, periodic pulses regulated by GHRH and somatostatin cross-talk. By utilizing the 'W/DAC' format, which binds covalently to serum albumin in biological systems, researchers can evaluate GHRH receptor binding and pituitary clearance kinetics under conditions of constant, prolonged stimulation. This is important for endocrine studies trying to analyze receptor desensitization and downregulation thresholds.

Current laboratory investigations examine CJC-1295 with DAC's interaction with pituitary GHRH receptors. Binding of the peptide activates the G-protein coupled receptor pathway, stimulating cyclic adenosine monophosphate (cAMP) accumulation, adenylate cyclase activity, and subsequent protein kinase A (PKA) phosphorylation. These intracellular cascades trigger the synthesis and release of growth hormone from somatotropic cells, allowing researchers to study signal transduction pathways under controlled in vitro and in vivo conditions.

Beyond pituitary receptor mechanics, researchers use CJC-1295 with DAC to explore downstream somatotrophic axis regulation. Studies evaluate how growth hormone release stimulated by GHRH receptor agonists coordinates hepatic insulin-like growth factor 1 (IGF-1) synthesis and release. This feedback loop is studied to analyze receptor sensitivity, cellular signaling thresholds, and homeostatic endocrine feedback mechanisms under conditions of constant GHRH agonist exposure.

The liquid spray formulation provides an optimized experimental vehicle for investigating non-invasive mucosal epithelial transport. Researchers analyze how the modified 29-amino-acid peptide crosses nasal or oral mucosal barriers, evaluating tight junction interactions and trans-epithelial transport rates. Additionally, in neurobiology, the intranasal spray format is investigated to study direct olfactory transport pathways bypass of the blood-brain barrier for CNS-somatotrophic axis studies.

Each bottle of CJC-1295 W/DAC 5mg spray is manufactured using solid-phase peptide synthesis (SPPS), followed by purification and conjugation steps to isolate the high-purity acylated peptide. The peptide is then dissolved in a stabilized, buffered aqueous solution calibrated to ensure exact concentration per metered spray activation. Quality control protocols include reverse-phase high-performance liquid chromatography (HPLC) for purity verification and liquid chromatography-mass spectrometry (LC-MS) for molecular identity confirmation.

To preserve the stability of the peptide in solution, CJC-1295 W/DAC Spray should be stored under refrigeration (2°C to 8°C) and protected from light. Because GHRH analogs can undergo oxidation or deamidation in aqueous environments over time, maintaining refrigerated storage and minimizing atmospheric exposure is critical to preserving peptide integrity. Proper handling supports consistent concentration and analytical reproducibility across laboratory protocols.

Scientific interest in CJC-1295 with DAC continues to expand as researchers seek to characterize its stability, receptor interactions, and transport kinetics. Nevertheless, many aspects of its cellular signaling and epithelial transport remain active areas of scientific inquiry. Ongoing studies continue to refine the understanding of GHRH analog behavior in biological systems. For this reason, CJC-1295 W/DAC 5mg spray should be regarded as an investigational compound whose primary value lies in advancing scientific knowledge of somatotropic receptor biology.

CJC-1295 W/DAC 5mg spray is supplied exclusively for laboratory research and analytical applications. It is intended for Research Use Only (RUO) and is not approved for human consumption, therapeutic use, veterinary use, or diagnostic purposes.